A Review of Antithrombotic Treatment in Critical Limb Ischemia After Endovascular Intervention

摘要: Endovascular intervention is often used to treat critical limb ischemia (CLI). Post-intervention treatment with antiplatelet and/or anticoagulant therapy has reduced morbidity and mortality due cardiovascular complications. The purpose of this review shed light on the various pharmacologic protocols for treating CLI following endovascular procedures. We reviewed literature comparing outcomes after antithrombotic patients CLI. characterized therapies into three categories: (1) mono-antiplatelet (MAPT) vs. dual (DAPT), (2) MAPT (AP) + anticoagulant (AC) therapy, (3) AC AP + AC therapy. Relevant results statistics were extracted determine differences in rates outcomes: re-stenosis, occlusion, target revascularization (TLR), (4) major amputation, (5) adverse cardiac events, (6) all-cause death, (7) bleeding. Studies suggest that DAPT reduces post-surgical restenosis, TLR, amputation diabetic patients, without increasing bleeding incidences, compared MAPT. Also, provides overall superior efficacy, no difference alone. Additionally, effects significant salvage, survival rates, cumulative rate above ankle or death. These might provide better than CLI, ideal may be related condition individual patient. However, studies few heterogenous small patient populations. Therefore, further large controlled are warranted confirm these outcomes.